Botulinum toxin for ductal stenosis and fistulas of the main salivary glands |
| |
| Affiliation: | 1. Department of Oral and Maxillofacial Surgery, Aix Marseille Université, APHM, IFSTTAR, LBA, CHU Conception, Marseille, France;2. Department of Oral and Maxillofacial Surgery, Aix Marseille Université, APHM, CHU Conception, Marseille, France;3. Department of Oral and Maxillofacial Surgery, Hôpital Laveran, boulevard Laveran, Marseille, France;4. Oral and Maxillofacial Surgery Department, Strasbourg University Hospital, Strasbourg, France;1. Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran;2. Department of Prosthodontics, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran;3. Department of Orthodontics, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran;4. Dental Materials Research Center, Institute of Health, Babol University of Medical Sciences, Babol, Iran;1. Unit of Oral and Maxillofacial Surgery, Oral Health Sciences Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India;2. Advanced Pediatric Centre, Postgraduate Institute of Medical Education and Research, Chandigarh;1. Department of Oral Surgery, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, and Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, Shanghai, China;2. Centre of 3D-Printing Translational Medicine, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;3. Department of Craniomaxillofacial and Plastic Surgery, Faculty of Dentistry, Alexandria University, Alexandria, Egypt |
| |
| Abstract: | This study was performed to present the authors’ experience with botulinum toxin therapy for salivary stenosis and salivary fistula in terms of the procedure, dosage, effectiveness, and complications. A retrospective study of all patients treated in the maxillofacial surgery department for salivary stenosis or fistula from January 2014 to September 2018 was performed. Intraglandular injections of incobotulinumtoxinA (Xeomin) were utilized. The frequency of relapse and the pain recorded before injection and at 3 months after each injection or fistula resolution were assessed. Swallowing dysfunction or any diffusion of toxin into the facial muscles was recorded. This study included 22 patients (mean age 53 years). Botulinum therapy was indicated for parotid duct stenosis in 14 patients, submandibular duct stenosis in four patients, and parotid fistula in four patients. The frequency of relapse (P = 0.0001) and pain level (P = 0.0001) decreased after botulinum therapy. The average duration of the botulinum effect was 4.50±2.00 months after the first injection. No complication was observed. Botulinum therapy with 100 IU of Xeomin proved effective at resolving salivary fistula. Botulinum therapy is an effective treatment for symptoms of salivary duct stenosis in patients for whom minimally invasive procedures have failed. Botulinum therapy can also be used for the treatment of salivary fistulas. |
| |
| Keywords: | stenosis salivary fistula parotid submandibular gland botulinum toxin |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
